Nobiletin Inhibits Breast Cancer Stem Cell by Regulating the Cell Cycle: A Comprehensive Bioinformatics Analysis and In Vitro Experiments

References

• Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022;66:15–23. 10.1016/j.breast.2022.08.010
   PubMed Web of Science ®Google Scholar
• Oliva D, Andersson B-Å, Nilsson M, Lewin N, Lewin F. Risk for relapse and death after adjuvant chemotherapy associated with SNPs in patients with breast cancer - a retrospective study. Cancer Treat Res Commun. 2022;30:100505. 10.1016/j.ctarc.2021.100505
   PubMedGoogle Scholar
• Riggio AI, Varley KE, Welm AL. The lingering mysteries of metastatic recurrence in breast cancer. Br J Cancer. 2021;124(1):13–26. 10.1038/s41416-020-01161-4
   PubMed Web of Science ®Google Scholar
• Ghanei Z, Jamshidizad A, Joupari MD, Shamsara M. Isolation and characterization of breast cancer stem cell-like phenotype by Oct4 promoter-mediated activity. J Cell Physiol. 2020;235(11):7840–8. 10.1002/jcp.29437
   PubMed Web of Science ®Google Scholar
• Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. Cancers (Basel). 2021;13(17):4287. 10.3390/cancers13174287
   PubMed Web of Science ®Google Scholar
• Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J, Zhang G, Wang X, Dong Z, Chen F, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020;5:8.
   PubMed Web of Science ®Google Scholar
• Morley KL, Ferguson PJ, Koropatnick J. Tangeretin and nobiletin induce G1 cell cycle arrest but not apoptosis in human breast and colon cancer cells. Cancer Lett. 2007;251(1):168–78. 10.1016/j.canlet.2006.11.016
   PubMed Web of Science ®Google Scholar
• Meiyanto E, Hermawan A, Junedi S, Fitriasari A, Susidarti RA. Nobiletin increased cytotoxic activity of doxorubicin on Mcf-7 cells but not on T47d cells. Int J Phytomed. 2011;3:129–37.
   Google Scholar
• Baek SH, Kim SM, Nam D, Lee JH, Ahn KS, Choi SH, Kim SH, Shim BS, Chang IM, Ahn KS. Antimetastatic effect of nobiletin through the down-regulation of CXC chemokine receptor type 4 and matrix metallopeptidase-9. Pharm Biol. 2012;50(10):1210–8. 10.3109/13880209.2012.664151
   PubMed Web of Science ®Google Scholar
• Shi MD, Liao YC, Shih YW, Tsai LY. Nobiletin attenuates metastasis via both ERK and PI3K/Akt pathways in HGF-treated liver cancer HepG2 cells. Phytomedicine. 2013;20(8-9):743–52. 10.1016/j.phymed.2013.02.004
   PubMed Web of Science ®Google Scholar
• Sp N, Kang DY, Joung YH, Park JH, Kim WS, Lee HK, Song KD, Park YM, Yang YM. Nobiletin inhibits angiogenesis by regulating Src/FAK/STAT3-mediated signaling through PXN in ER(+) breast cancer cells. Int J Mol Sci. 2017;18(5):935. 10.3390/ijms18050935
   PubMed Web of Science ®Google Scholar
• Du J, Yan X, Mi S, Li Y, Ji H, Hou K, Ma S, Ba Y, Zhou P, Chen L, et al. Identification of prognostic model and biomarkers for cancer stem cell characteristics in glioblastoma by network analysis of multi-omics data and stemness indices. Front Cell Dev Biol. 2020;8:558961. 10.3389/fcell.2020.558961
   PubMed Web of Science ®Google Scholar
• Hermawan A, Ikawati M, Jenie RI, Khumaira A, Putri H, Nurhayati IP, Angraini SM, Muflikhasari HA. Identification of potential therapeutic target of naringenin in breast cancer stem cells inhibition by bioinformatics and in vitro studies. Saudi Pharm J. 2021a;29(1):12–26. 10.1016/j.jsps.2020.12.002
   PubMed Web of Science ®Google Scholar
• Hermawan A, Ikawati M, Khumaira A, Putri H, Jenie RI, Angraini SM, Muflikhasari HA. Bioinformatics and in vitro studies reveal the importance of p53, PPARG and notch signaling pathway in inhibition of breast cancer stem cells by hesperetin. Adv Pharm Bull. 2021b;11(2):351–60. 10.34172/apb.2021.033
   PubMed Web of Science ®Google Scholar
• Brugnoli F, Grassilli S, Al-Qassab Y, Capitani S, Bertagnolo V. CD133 in breast cancer cells: more than a stem cell marker. J Oncol. 2019;2019:7512632. 10.1155/2019/7512632
   PubMed Web of Science ®Google Scholar
• Hermawan A, Putri H, Fatimah N, Prasetio HH. Transcriptomics analysis reveals distinct mechanism of breast cancer stem cells regulation in mammospheres from MCF-7 and T47D cells. Heliyon. 2024;10(2):e24356. 10.1016/j.heliyon.2024.e24356
   PubMed Web of Science ®Google Scholar
• Oak PS, Kopp F, Thakur C, Ellwart JW, Rapp UR, Ullrich A, Wagner E, Knyazev P, Roidl A. Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2-positive cancer cells and cancer stem cells. Int J Cancer. 2012;131(12):2808–19. 10.1002/ijc.27595
   PubMed Web of Science ®Google Scholar
• Hermawan A, Khumaira A, Ikawati M, Putri H, Jenie RI, Angraini SM, Muflikhasari HA. Identification of key genes of hesperidin in inhibition of breast cancer stem cells by functional network analysis. Comput Biol Chem. 2021c;90:107427. 10.1016/j.compbiolchem.2020.107427
   PubMed Web of Science ®Google Scholar
• Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol. 2016;34(5):525–7. 10.1038/nbt.3519
   PubMed Web of Science ®Google Scholar
• Robinson MD, McCarthy DJ, Smyth GK. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139–40. 10.1093/bioinformatics/btp616
   PubMed Web of Science ®Google Scholar
• Wang J, Vasaikar S, Shi Z, Greer M, Zhang B. WebGestalt 2017: a more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit. Nucleic Acids Res. 2017;45(W1):W130–w137. 10.1093/nar/gkx356
   PubMed Web of Science ®Google Scholar
• Qi X, Huang Q, Wang S, Qiu L, Chen X, Ouyang K, Chen Y. Identification of the shared mechanisms and common biomarkers between Sjögren’s syndrome and atherosclerosis using integrated bioinformatics analysis. Front Med (Lausanne). 2023;10:1185303. 10.3389/fmed.2023.1185303
   PubMed Web of Science ®Google Scholar
• Skolastika S, Hanif N, Ikawati M, Hermawan A. Comprehensive computational analysis of honokiol targets for cell cycle inhibition and immunotherapy in metastatic breast cancer stem cells. Evid Based Complement Alternat Med. 2022;2022:4172531. 10.1155/2022/4172531
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–d613. 10.1093/nar/gky1131
   PubMed Web of Science ®Google Scholar
• Yao Z, Zhang B, Niu G, Yan Z, Tong X, Zou Y, Li Y, Yang M. Neutrophil infiltration characterized by upregulation of S100A8, S100A9, S100A12 and CXCR2 is associated with the co-occurrence of Crohn’s disease and peripheral artery disease. Front Immunol. 2022;13:896645. 10.3389/fimmu.2022.896645
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1. 10.1126/scisignal.2004088
   PubMed Web of Science ®Google Scholar
• Gao J, Lindsay J, Watt S, Bahceci I, Lukasse P, Abeshouse A, Chen H-W, de Bruijn I, Gross B, Li D. 2016. The cBioPortal for cancer genomics and its application in precision oncology. AACR.
   Google Scholar
• Győrffy B. Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Comput Struct Biotechnol J. 2021;19:4101–9. 10.1016/j.csbj.2021.07.014
   PubMed Web of Science ®Google Scholar
• Li C, Tang Z, Zhang W, Ye Z, Liu F. GEPIA2021: integrating multiple deconvolution-based analysis into GEPIA. Nucleic Acids Res. 2021;49(W1):W242–w246. 10.1093/nar/gkab418
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017b;45(W1):W98–w102. 10.1093/nar/gkx247
   PubMed Web of Science ®Google Scholar
• Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, et al. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419. 10.1126/science.1260419
   PubMed Web of Science ®Google Scholar
• Uhlen M, Zhang C, Lee S, Sjöstedt E, Fagerberg L, Bidkhori G, Benfeitas R, Arif M, Liu Z, Edfors F, et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357(6352):eaan2507. 10.1126/science.aan2507
   PubMed Web of Science ®Google Scholar
• St-Denis N, Gupta GD, Lin ZY, Gonzalez-Badillo B, Pelletier L, Gingras AC. Myotubularin-related proteins 3 and 4 interact with polo-like kinase 1 and centrosomal protein of 55 kDa to ensure proper abscission. Mol Cell Proteomics. 2015;14(4):946–60. 10.1074/mcp.M114.046086
   PubMed Web of Science ®Google Scholar
• Naughtin MJ, Sheffield DA, Rahman P, Hughes WE, Gurung R, Stow JL, Nandurkar HH, Dyson JM, Mitchell CA. The myotubularin phosphatase MTMR4 regulates sorting from early endosomes. J Cell Sci. 2010;123(Pt 18):3071–83. 10.1242/jcs.060103
   PubMed Web of Science ®Google Scholar
• Sheffield DA, Jepsen MR, Feeney SJ, Bertucci MC, Sriratana A, Naughtin MJ, Dyson JM, Coppel RL, Mitchell CA. The myotubularin MTMR4 regulates phagosomal phosphatidylinositol 3-phosphate turnover and phagocytosis. J Biol Chem. 2019;294(45):16684–97. 10.1074/jbc.RA119.009133
   PubMed Web of Science ®Google Scholar
• Xia X, Liao Y, Guo Z, Li Y, Jiang L, Zhang F, Huang C, Liu Y, Wang X, Liu N, et al. Targeting proteasome-associated deubiquitinases as a novel strategy for the treatment of estrogen receptor-positive breast cancer. Oncogenesis. 2018;7(9):75. 10.1038/s41389-018-0086-y
   PubMedGoogle Scholar
• Ding F, Ma JL, Wu XW, Liu ZH. [Influence of UCHL5 on proliferation and apoptosis of SW527 breast cancer cells]. Zhonghua Zhong Liu Za Zhi. 2018;40(12):900–4. 10.3760/cma.j.issn.0253-3766.2018.12.005
   PubMedGoogle Scholar
• Fukui S, Nagasaka K, Miyagawa Y, Kikuchi-Koike R, Kawata Y, Kanda R, Ichinose T, Sugihara T, Hiraike H, Wada-Hiraike O, et al. The proteasome deubiquitinase inhibitor bAP15 downregulates TGF-β/Smad signaling and induces apoptosis via UCHL5 inhibition in ovarian cancer. Oncotarget. 2019;10(57):5932–48. 10.18632/oncotarget.27219
   PubMedGoogle Scholar
• Ahmed ZSO, Li X, Li F, Cheaito HA, Patel K, Mosallam EM, Elbargeesy G, Dou QP. Computational and biochemical studies of isothiocyanates as inhibitors of proteasomal cysteine deubiquitinases in human cancer cells. J Cell Biochem. 2018;119(11):9006–16. 10.1002/jcb.27157
   PubMed Web of Science ®Google Scholar
• Chow P-M, Dong J-R, Chang Y-W, Kuo K-L, Lin W-C, Liu S-H, Huang K-H. The UCHL5 inhibitor b-AP15 overcomes cisplatin resistance via suppression of cancer stemness in urothelial carcinoma. Mol Ther Oncolytics. 2022;26:387–98. 10.1016/j.omto.2022.08.004
   PubMed Web of Science ®Google Scholar
• Kaushal K, Ramakrishna S. Deubiquitinating enzyme-mediated signaling networks in cancer stem cells. Cancers (Basel). 2020;12(11):3253. 10.3390/cancers12113253
   PubMed Web of Science ®Google Scholar
• Arpalahti L, Hagström J, Mustonen H, Lundin M, Haglund C, Holmberg CI. UCHL5 expression associates with improved survival in lymph-node-positive rectal cancer. Tumour Biol. 2017a;39(7):1010428317716078. 10.1177/1010428317716078
   Google Scholar
• Arpalahti L, Saukkonen K, Hagström J, Mustonen H, Seppänen H, Haglund C, Holmberg CI. Nuclear ubiquitin C-terminal hydrolase L5 expression associates with increased patient survival in pancreatic ductal adenocarcinoma. Tumour Biol. 2017b;39(6):1010428317710411. 10.1177/1010428317710411
   Google Scholar
• Arpalahti L, Laitinen A, Hagström J, Mustonen H, Kokkola A, Böckelman C, Haglund C, Holmberg CI. Positive cytoplasmic UCHL5 tumor expression in gastric cancer is linked to improved prognosis. PLoS One. 2018;13(2):e0193125. 10.1371/journal.pone.0193125
   PubMed Web of Science ®Google Scholar
• Ayad NG. CDKs give Cdc6 a license to drive into S phase. Cell. 2005;122(6):825–7. 10.1016/j.cell.2005.09.001
   PubMed Web of Science ®Google Scholar
• Borlado LR, Méndez J. CDC6: from DNA replication to cell cycle checkpoints and oncogenesis. Carcinogenesis. 2008;29(2):237–43. 10.1093/carcin/bgm268
   PubMed Web of Science ®Google Scholar
• Chen S, Chen X, Xie G, He Y, Yan D, Zheng D, Li S, Fu X, Li Y, Pang X, et al. Cdc6 contributes to cisplatin-resistance by activation of ATR-Chk1 pathway in bladder cancer cells. Oncotarget. 2016;7(26):40362–76. 10.18632/oncotarget.9616
   PubMed Web of Science ®Google Scholar
• Mahadevappa R, Neves H, Yuen SM, Bai Y, McCrudden CM, Yuen HF, Wen Q, Zhang SD, Kwok HF. The prognostic significance of Cdc6 and Cdt1 in breast cancer. Sci Rep. 2017;7(1):985. 10.1038/s41598-017-00998-9
   PubMedGoogle Scholar
• Kim YH, Byun YJ, Kim WT, Jeong P, Yan C, Kang HW, Kim YJ, Lee SC, Moon SK, Choi YH, et al. CDC6 mRNA expression is associated with the aggressiveness of prostate cancer. J Korean Med Sci. 2018;33(47):e303. 10.3346/jkms.2018.33.e303
   PubMed Web of Science ®Google Scholar
• Kong DG, Yao FZ. CDC6 is a possible biomarker for hepatocellular carcinoma. Int J Clin Exp Pathol. 2021;14(7):811–8.
   PubMed Web of Science ®Google Scholar
• Zhao H, Zhou X, Yuan G, Hou Z, Sun H, Zhai N, Huang B, Li X. CDC6 is up-regulated and a poor prognostic signature in glioblastoma multiforme. Clin Transl Oncol. 2021;23(3):565–71. 10.1007/s12094-020-02449-w
   PubMed Web of Science ®Google Scholar
• Yicong Y, Wang Y, Denglong W, Baoying H. Increased CDC6 expression associates with poor prognosis in patients with clear cell renal cell carcinoma. Front Oncol. 2021;11:666418. 10.3389/fonc.2021.666418
   PubMed Web of Science ®Google Scholar
• Jiang W, Yu Y, Liu J, Zhao Q, Wang J, Zhang J, Dang X. Downregulation of Cdc6 inhibits tumorigenesis of osteosarcoma in vivo and in vitro. Biomed Pharmacother. 2019;115:108949. 10.1016/j.biopha.2019.108949
   PubMed Web of Science ®Google Scholar
• Bömer M, Pérez-Salamó I, Florance HV, Salmon D, Dudenhoffer JH, Finch P, Cinar A, Smirnoff N, Harvey A, Devoto A. Jasmonates induce Arabidopsis bioactivities selectively inhibiting the growth of breast cancer cells through CDC6 and mTOR. New Phytol. 2021;229(4):2120–34. 10.1111/nph.17031
   PubMed Web of Science ®Google Scholar
• Tang A, Gao K, Chu L, Zhang R, Yang J, Zheng J. Aurora kinases: novel therapy targets in cancers. Oncotarget. 2017a;8(14):23937–54. 10.18632/oncotarget.14893
   PubMedGoogle Scholar
• Wang Z, Yu Z, Wang GH, Zhou YM, Deng JP, Feng Y, Chen JQ, Tian L. AURKB promotes the metastasis of gastric cancer, possibly by inducing EMT. Cancer Manag Res. 2020b;12:6947–58. 10.2147/CMAR.S254250
   PubMed Web of Science ®Google Scholar
• Zhang J, Lin X, Wu L, Huang JJ, Jiang WQ, Kipps TJ, Zhang S. Aurora B induces epithelial-mesenchymal transition by stabilizing Snail1 to promote basal-like breast cancer metastasis. Oncogene. 2020;39(12):2550–67. 10.1038/s41388-020-1165-z
   PubMed Web of Science ®Google Scholar
• Zhang Y, Jiang C, Li H, Lv F, Li X, Qian X, Fu L, Xu B, Guo X. Elevated Aurora B expression contributes to chemoresistance and poor prognosis in breast cancer. Int J Clin Exp Pathol. 2015;8:751–7.
   PubMedGoogle Scholar
• Liu M, Li Y, Zhang C, Zhang Q. Role of aurora kinase B in regulating resistance to paclitaxel in breast cancer cells. Hum Cell. 2022;35(2):678–93. 10.1007/s13577-022-00675-8
   PubMed Web of Science ®Google Scholar
• Shin SY, Lee Y, Kim BS, Lee J, Ahn S, Koh D, Lim Y, Lee YH. Inhibitory effect of synthetic flavone derivatives on pan-aurora kinases: induction of G2/M cell-cycle arrest and apoptosis in HCT116 human colon cancer cells. Int J Mol Sci. 2018;19(12):4086. 10.3390/ijms19124086
   PubMed Web of Science ®Google Scholar
• Romagnolo AP, Romagnolo DF, Selmin OI. BRCA1 as target for breast cancer prevention and therapy. Anticancer Agents Med Chem. 2015;15(1):4–14. 10.2174/1871520614666141020153543
   PubMed Web of Science ®Google Scholar
• Shafee N, Smith CR, Wei S, Kim Y, Mills GB, Hortobagyi GN, Stanbridge EJ, Lee EY-HP. Cancer stem cells contribute to cisplatin resistance in Brca1/p53–mediated mouse mammary tumors. Cancer Res. 2008;68(9):3243–50. 10.1158/0008-5472.CAN-07-5480
   PubMed Web of Science ®Google Scholar
• Kim H, Lin Q, Yun Z. BRCA1 regulates the cancer stem cell fate of breast cancer cells in the context of hypoxia and histone deacetylase inhibitors. Sci Rep. 2019;9(1):9702. 10.1038/s41598-019-46210-y
   PubMedGoogle Scholar
• You Y, Bi FF, Jiang Y, Xu YT, An YY, Li D, Yang Q. BRCA1 affects the resistance and stemness of SKOV3-derived ovarian cancer stem cells by regulating autophagy. Cancer Med. 2019;8(2):656–68. 10.1002/cam4.1975
   PubMed Web of Science ®Google Scholar
• Nathansen J, Meyer F, Müller L, Schmitz M, Borgmann K, Dubrovska A. Beyond the double-strand breaks: the role of DNA repair proteins in cancer stem-cell regulation. Cancers (Basel). 2021;13(19):4818. 10.3390/cancers13194818
   PubMed Web of Science ®Google Scholar
• Nielsen CF, Zhang T, Barisic M, Kalitsis P, Hudson DF. Topoisomerase IIα is essential for maintenance of mitotic chromosome structure. Proc Natl Acad Sci USA. 2020;117(22):12131–42. 10.1073/pnas.2001760117
   PubMed Web of Science ®Google Scholar
• Romero A, Martín M, Cheang MC, López García-Asenjo JA, Oliva B, He X, de la Hoya M, García Sáenz J, Arroyo Fernández M, Díaz Rubio E, et al. Assessment of topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization. Am J Pathol. 2011;178(4):1453–60. 10.1016/j.ajpath.2010.12.042
   PubMed Web of Science ®Google Scholar
• Zhong W, Yang Y, Zhang A, Lin W, Liang G, Ling Y, Zhong J, Yong J, Liu Z, Tian Z, et al. Prognostic and predictive value of the combination of TOP2A and HER2 in node-negative tumors 2 cm or smaller (T1N0) breast cancer. Breast Cancer. 2020;27(6):1147–57. 10.1007/s12282-020-01142-8
   PubMed Web of Science ®Google Scholar
• Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, Hannon GJ, Lowe SW, Hemann MT. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci USA. 2008;105(26):9053–8. 10.1073/pnas.0803513105
   PubMed Web of Science ®Google Scholar
• Wang B, Shen Y, Zou Y, Qi Z, Huang G, Xia S, Gao R, Li F, Huang Z. TOP2A promotes cell migration, invasion and epithelial-mesenchymal transition in cervical cancer via activating the PI3K/AKT signaling. Cancer Manag Res. 2020a;12:3807–14. 10.2147/CMAR.S240577
   PubMed Web of Science ®Google Scholar
• Li X, Liu Y, Chen W, Fang Y, Xu H, Zhu HH, Chu M, Li W, Zhuang G, Gao WQ. TOP2Ahigh is the phenotype of recurrence and metastasis whereas TOP2Aneg cells represent cancer stem cells in prostate cancer. Oncotarget. 2014;5(19):9498–513. 10.18632/oncotarget.2411
   PubMedGoogle Scholar
• Maugeri-Saccà M, Bartucci M, De Maria R. Checkpoint kinase 1 inhibitors for potentiating systemic anticancer therapy. Cancer Treat Rev. 2013;39(5):525–33. 10.1016/j.ctrv.2012.10.007
   PubMed Web of Science ®Google Scholar
• Abdel-Fatah TM, Middleton FK, Arora A, Agarwal D, Chen T, Moseley PM, Perry C, Doherty R, Chan S, Green AR, et al. Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer. Mol Oncol. 2015;9(3):569–85. 10.1016/j.molonc.2014.10.013
   PubMed Web of Science ®Google Scholar
• Bartucci M, Svensson S, Romania P, Dattilo R, Patrizii M, Signore M, Navarra S, Lotti F, Biffoni M, Pilozzi E, et al. Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. Cell Death Differ. 2012;19(5):768–78. 10.1038/cdd.2011.170
   PubMed Web of Science ®Google Scholar
• Zhang P, Wei Y, Wang L, Debeb BG, Yuan Y, Zhang J, Yuan J, Wang M, Chen D, Sun Y, et al. ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1. Nat Cell Biol. 2014b;16(9):864–75. 10.1038/ncb3013
   PubMed Web of Science ®Google Scholar
• Manic G, Signore M, Sistigu A, Russo G, Corradi F, Siteni S, Musella M, Vitale S, De Angelis ML, Pallocca M, et al. CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells. Gut. 2018;67(5):903–17. 10.1136/gutjnl-2016-312623
   PubMed Web of Science ®Google Scholar
• Wen Y, Hou Y, Yi X, Sun S, Guo J, He X, Li T, Cai J, Wang Z. EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells. Theranostics. 2021;11(4):1795–813. 10.7150/thno.48101
   PubMed Web of Science ®Google Scholar
• Keijzers G, Bakula D, Petr MA, Madsen NGK, Teklu A, Mkrtchyan G, Osborne B, Scheibye-Knudsen M. Human exonuclease 1 (EXO1) regulatory functions in DNA replication with putative roles in cancer. Int J Mol Sci. 2018;20(1):74. 10.3390/ijms20010074
   PubMed Web of Science ®Google Scholar
• Muthuswami M, Ramesh V, Banerjee S, Viveka Thangaraj S, Periasamy J, Bhaskar Rao D, Barnabas GD, Raghavan S, Ganesan K. Breast tumors with elevated expression of 1q candidate genes confer poor clinical outcome and sensitivity to Ras/PI3K inhibition. PLoS One. 2013;8(10):e77553. 10.1371/journal.pone.0077553
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang J. Elevated EXO1 expression is associated with breast carcinogenesis and poor prognosis. Ann Transl Med. 2021;9(2):135–10.21037/atm-20-7922
   PubMed Web of Science ®Google Scholar
• Pei J, Wang Y, Li Y. Identification of key genes controlling breast cancer stem cell characteristics via stemness indices analysis. J Transl Med. 2020;18(1):74. 10.1186/s12967-020-02260-9
   PubMed Web of Science ®Google Scholar
• Zhang J, Yang R, Zhou D, Rudolph KL, Meng A, Ju Z. Exonuclease 1 is essential for maintaining genomic stability and the proliferative capacity of neural but not hematopoietic stem cells. Stem Cell Res. 2014a;12(1):250–9. 10.1016/j.scr.2013.11.001
   PubMed Web of Science ®Google Scholar
• Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer. 2011;2(4):466–74. 10.1177/1947601911408889
   PubMedGoogle Scholar
• Ghatak D, Das Ghosh D, Roychoudhury S. Cancer stemness: p53 at the Wheel. Front Oncol. 2020;10:604124. 10.3389/fonc.2020.604124
   PubMed Web of Science ®Google Scholar
• Wang QE. DNA damage responses in cancer stem cells: implications for cancer therapeutic strategies. World J Biol Chem. 2015;6(3):57–64. 10.4331/wjbc.v6.i3.57
   PubMedGoogle Scholar
• Caglar HO, Biray Avci C. Alterations of cell cycle genes in cancer: unmasking the role of cancer stem cells. Mol Biol Rep. 2020;47(4):3065–76. 10.1007/s11033-020-05341-6
   PubMed Web of Science ®Google Scholar
• Khan FH, Dervan E, Bhattacharyya DD, McAuliffe JD, Miranda KM, Glynn SA. The role of nitric oxide in cancer: master regulator or not? Int J Mol Sci. 2020;21(24):9393. 10.3390/ijms21249393
   PubMed Web of Science ®Google Scholar
• Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017;17(2):93–115. 10.1038/nrc.2016.138
   PubMed Web of Science ®Google Scholar
• Clay-Farrace L, Pelizon C, Santamaria D, Pines J, Laskey RA. Human replication protein Cdc6 prevents mitosis through a checkpoint mechanism that implicates Chk1. Embo J. 2003;22(3):704–12. 10.1093/emboj/cdg046
   PubMed Web of Science ®Google Scholar
• Sankhe K, Prabhu A, Khan T. Design strategies, SAR, and mechanistic insight of Aurora kinase inhibitors in cancer. Chem Biol Drug Des. 2021;98(1):73–93. 10.1111/cbdd.13850
   PubMed Web of Science ®Google Scholar
• Sasanuma H, Tsuda M, Morimoto S, Saha LK, Rahman MM, Kiyooka Y, Fujiike H, Cherniack AD, Itou J, Callen Moreu E, et al. BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II–DNA complexes. Proc Natl Acad Sci USA. 2018;115(45):E10642–E10651. 10.1073/pnas.1803177115
   PubMed Web of Science ®Google Scholar
• Borah NA, Reddy MM. Aurora kinase B inhibition: a potential therapeutic strategy for cancer. Molecules. 2021;26(7):1981. 10.3390/molecules26071981
   PubMed Web of Science ®Google Scholar
• Tomimatsu N,Mukherjee B,Harris JL,Boffo FL,Hardebeck MC,Potts PR,Khanna KK,Burma S. DNA-damage-induced degradation of EXO1 exonuclease limits DNA end resection to ensure accurate DNA repair. J Biol Chem. 2017;292(26):10779–90. 10.1074/jbc.M116.772475. 28515316
   PubMed Web of Science ®Google Scholar
• Jiang ZY, Hong J, Zhang JH, Wang XF, Ma YS, Xiong ZX, Sun HR, Cheng C, Xie BZ, Liu JB, et al. Treatment with b-AP15 to inhibit UCHL5 and USP14 deubiquitinating activity and enhance p27 and cyclin E1 for tumors with p53 deficiency. Technol Cancer Res Treat. 2022;21:15330338221119745. 10.1177/15330338221119745
   Web of Science ®Google Scholar